Kevin E. Lofton's most recent trade in Medtronic Plc was a trade of 2,111 Ordinary Shares done . Disclosure was reported to the exchange on April 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2026 | 2,111 | 10,347 (0%) | 0% | 0 | Ordinary Shares | |
| Medtronic | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.90 per share. | 27 Apr 2026 | 207 | 10,140 (0%) | 0% | 81.9 | 16,953 | Ordinary Shares |
| MiniMed Group Inc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2026 | 27,778 | 27,778 | - | 0 | Common Stock | |
| Medtronic | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 84.04 per share. | 28 Apr 2025 | 2,083 | 8,387 (0%) | 0% | 84.0 | 175,055 | Ordinary Shares |
| Medtronic | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.60 per share. | 28 Apr 2025 | 216 | 8,171 (0%) | 0% | 84.6 | 18,274 | Ordinary Shares |
| Medtronic | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 6,230 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Medtronic | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 6,422 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Gilead Sciences | Lofton E. Kevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 29 | 3,224 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 31 | 3,194 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 30 | 3,163 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 92,653 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 May 2023 | 12,868 | 90,766 (0%) | 0% | 0 | Common Stock | |
| Medtronic | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 4,360 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Medtronic | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 4,191 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 28 | 3,132 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 8,442 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.38 per share. | 09 Mar 2023 | 8,442 | 8,442 (0%) | 0% | 52.4 | 442,192 | Common Stock |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2022 | 26 | 3,103 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2022 | 35 | 3,077 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 35 | 3,042 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 95,192 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 92,748 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 9,830 | - | - | Restricted Stock Unit | |
| Medtronic | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 2,535 (0%) | 0% | 0 | Ordinary Shares | |
| Medtronic | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 161 | 2,374 (0%) | 0% | 103.1 | 16,601 | Ordinary Shares |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.62 per share. | 28 Apr 2022 | 16,322 | 90,525 (0%) | 0% | 25.6 | 418,251 | Common Stock |
| Gilead Sciences | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 16,322 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 36 | 3,007 | - | - | Phantom Stock | |
| Gilead Sciences | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2021 | 29 | 2,942 | - | - | Phantom Stock |